The H6PD Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the A-549 human lung epithelial cell line, in which the H6PD gene has been disrupted to create a loss-of-function model. This polyclonal knockout pool, generated without single-cell cloning, offers a genetically heterogeneous population with varied H6PD editing events, enabling robust functional studies without the bias of a single clonal isolate. The use of CRISPR/Cas9-mediated gene disruption ensures efficient and specific targeting of H6PD while preserving the overall cellular background.
The host A-549 cell line, originally established from a 58-year-old Caucasian male with lung adenocarcinoma, exhibits an adherent epithelial morphology and characteristics of alveolar Type II pneumocytes. A-549 cells are widely employed in biomedical research as a model to study lung adenocarcinoma biology, pulmonary drug metabolism, and respiratory viral infection. Their epithelial origin and retention of key metabolic pathways make them a relevant system for examining glucocorticoid homeostasis and endoplasmic reticulum (ER) redox regulation in a cancer context.
H6PD (hexose-6-phosphate dehydrogenase) oxidizes glucose-6-phosphate to 6-phosphogluconolactone in the ER lumen, generating a dedicated pool of NADPH. This luminal NADPH is essential for the activity of 11??-hydroxysteroid dehydrogenase type 1 (HSD11B1), which converts inactive cortisone to active cortisol. Cortisol then binds the glucocorticoid receptor (NR3C1) and regulates transcription of target genes such as FKBP5 and GILZ. H6PD activity is regulated by factors including glucose-6-phosphate, NADP+ levels, insulin signaling, and ER stress, and it functionally couples with HSD11B1. Knockout of H6PD severs this NADPH supply, disrupting local cortisol activation and downstream glucocorticoid-responsive gene networks.
Within A-549 lung adenocarcinoma cells, H6PD knockout disrupts the ER luminal NADPH pool, leading to diminished HSD11B1-dependent cortisol synthesis. Since glucocorticoids modulate cancer cell proliferation, apoptosis, migration, and the tumor microenvironment, this loss-of-function model provides a relevant system to study how local glucocorticoid inactivation impacts alveolar Type II-like cell biology. The disruption also mimics metabolic features of apparent cortisone reductase deficiency and offers a tool to probe ER redox homeostasis in a disease-relevant epithelial context.
This polyclonal knockout population enables studies on glucocorticoid metabolism in lung cancer, ER redox regulation, cortisone reductase deficiency, HSD11B1 modulator screening, and tumor microenvironment interactions. Common techniques include western blotting for H6PD and HSD11B1, RT-qPCR for FKBP5 and other glucocorticoid-responsive genes, intracellular cortisol ELISA or LC-MS/MS, NADP+/NADPH quantification, glucocorticoid receptor transactivation reporter assays, and functional assays for cell proliferation, apoptosis, and migration. For further details or custom solutions, please contact Ascent Research.
